Despite the success of contemporary treatment protocols in childhood acute lymphoblastic leukaemia (ALL), relapse within the central nervous system (CNS) remains a challenge. To better understand this phenomenon, we have analysed the changes in incidence and pattern of CNS relapses in 5564 children enrolled in four successive Medical Research Council-ALL trials between 1985 and 2001. Changes in the incidence and pattern of CNS relapses were examined and the relationship with patient characteristics was assessed. The factors affecting outcome after relapse were determined. Overall, relapses declined by 49%. Decreases occurred primarily in non-CNS and combined relapses with a progressive shift towards later (X30 months from diagnosis) relapses (Po0.0001). Although isolated CNS relapses declined, the proportional incidence and timing of relapse remained unchanged. Age and presenting white blood cell (WBC) count were risk factors for CNS relapse. On multivariate analysis, the time to relapse and the trial period influenced outcomes after relapse. Relapse trends differed within biological subtypes. In ETV6-RUNX1 ALL, relapse patterns mirrored overall trends whereas in high hyperdiploidy (HH) ALL, these seem to have plateaued over the latter two trial periods. Intensive systemic and intrathecal chemotherapy have decreased the overall CNS relapse rates and changed the patterns of recurrence. The heterogeneity of therapeutic response in the biological subtypes suggests room for further optimization using currently available chemotherapy.
Introduction
Over the last three decades, survival of children with acute lymphoblastic leukaemia (ALL) has improved from approximately 50% 1 to nearly 80%. 2 During the same period the outcome for those who relapse has remained poor. [3] [4] [5] [6] [7] [8] [9] Relapses result when evolutionary pressures of frontline therapy favour emergence of a subclone from within the original blast population. 10 The incidence and pattern of relapses thus vary according to the protocols used. Irrespective of frontline treatment, relapsed ALL is characterized by two recurring features. The first is the critical prognostic effect of the duration of first complete remission. 3, [7] [8] [9] 11 Patients who relapse within 18 months of initial diagnosis have a significantly worse outcome when compared with those with later relapses. The second is the predilection for relapse in extramedullary sites, particularly the central nervous system (CNS). At initial diagnosis, o2% of children have disease within the CNS. This can rise to 40% at first relapse. 3, 7, 9 CNS relapses may occur isolated or in conjunction with marrow disease (combined relapse)Ftherapy outcomes seem to differ in these two groups. In a Children's Oncology Group report of standard-risk ALL relapses, overall survival (OS) was better in children with isolated extramedullary rather than combined relapse. 8 The advent of sensitive molecular investigations has complicated the distinction between these two relapse categories. For instance, the Berlin-Frankfurt-Mü nster group observed that B80% of those with apparent isolated CNS relapse had molecular evidence of marrow disease. Although the numbers are small and are not adjusted for the duration of first complete remission, the observations of this group similarly suggest that the higher the concomitant marrow tumour burden, the worse the outcome of extramedullary relapses. 12 We do not know why relapses occur in the CNS. Within the limitations of our understanding, modern ALL protocols are designed to limit CNS relapses. Over the last three decades in the United Kingdom and elsewhere, intrathecal chemotherapy has replaced cranial irradiation as CNS-directed prophylaxis for most children with ALL. 13 Along with progressive intensification of systemic therapy, these measures have in general been successful and the overall incidence of CNS relapses has steadily declined. 2 Nevertheless, CNS relapse remains a significant preventable and therapeutic challenge. What then has been the effect of modern therapies on the pattern of CNS relapses in childhood ALL? Have we reached the end of optimization with conventional drugs or is there room for further refinement of existing therapy? To answer these questions, we have analysed the trends in incidence and outcome of CNS relapses among children treated for ALL in the United Kingdom over a 17-year period spanning four trial eras. The 5-year eventfree survival (EFS) improved from approximately 60% 14 to nearly 80% 15 during this period.
Patients and methods

Patients
All patients, treated on national protocols for childhood ALL between 1985 and 2001 and who experienced a relapse in the CNS, were included in these analyses. Patients with a non-CNS relapse (n-CNSr) were included for comparison. For purposes of this study, an isolated CNS relapse (i-CNSr) was defined as the presence of X5 white blood cells (WBCs) per ml in cerebrospinal fluid with blasts identified on cytospin, or a biopsyproven recurrence in the CNS or eye, in the absence of morphological disease in the bone marrow. A combined relapse (c-CNSr) was defined as the presence of CNS disease with X5% blasts in the bone marrow aspirate. Patients aged 1-9.99 years at presentation with diagnostic WBC counts o50 Â 10 9 /l were designated National Cancer Institute (NCI) standard risk; all other patients were classified as NCI high risk. Relapses were categorized as very early, early or late based on time to relapse from first diagnosis, that is, o18 months, 18-30 months or X30 months, respectively.
Clinical trials
The Medical Research Council clinical trials that ran during this period have previously been reported and include, chronologically, UKALLX, 16 UKALLXI 17,18 and ALL97. 15, 19 A major amendment was made to ALL97 in 1999 and the second phase of this trial is analysed separately (ALL97/99). 20 Salient relevant differences between the trials are outlined in Table 1 and  Supplementary Table S1 . For purposes of analyses, patients have been grouped according to the category of relapse (i-CNSr, c-CNSr or n-CNSr), NCI risk group, time to relapse and immunophenotype. 7 Analyses were based on the annual follow-up of 30 April 2007 for UKALLX and UKALLXI and of 31 October 2007 for ALL97 and ALL97/99. The small numbers of patients lost to follow-up were censored at the date of last contact. Median follow-up from commencement of treatment for UKALLX is 18.6 (range 0.0-22.3) years, for UKALLXI is 13.0 (range 0.3-16.6) years, for ALL97 is 9.3 (range 3.5-10.8) years and for ALL97/99 is 6.6 (range 2.3-8.0) years.
Cytogenetic and molecular genetic characterization
Diagnostic cytogenetics was performed at regional laboratories and karyotypes were confirmed centrally. 21 Some UKALLXI patients treated after 1994 were screened for ETV6-RUNX1 fusion using reverse transcriptase-polymerase chain reaction. 18 Fluorescent in situ hybridization analyses for ETV6-RUNX1 and other translocations became routine from the start of ALL97. High hyperdiploidy (HH) was characterized by karyotyping (51-65 chromosomes) or by centromere fluorescent in situ hybridization (using the Multiprobe-I system (Cytocell, Cambridge, UK) or by detection of classic trisomies). 22 Patients were classified as having a mixed-lineage leukaemia (MLL) rearrangement if an established 11q23/MLL translocation was observed on karyotyping or if a split signal pattern was observed using a break-apart MLL fluorescent in situ hybridization probe.
Statistical methods
The analyses of relapse excluded patients who died without achieving remission. Differences in clinical features, cytogenetics and proportions of relapses between patients enrolled on the distinct protocols were analysed using the w 2 test. The long follow-up means that analyses using simple proportions are equivalent to competing risk cumulative incidence calculations. These proportions indicate the number of patients experiencing an event of interest given the level of competing events and, when added for the different relapse categories, provide the total relapse rate. Kaplan-Meier life tables were constructed for survival curves and trials were compared using the log-rank test. Patients were censored at events other than the one of interest. Secondary malignant neoplasms (SMNs) were included in EFS estimations (Table 1 ) and all post-SMN relapses (overall, 3) were included in the analyses. The OS after relapse was defined as the time between first relapse and death from any cause. Univariate analyses using log-rank tests were performed to examine the significance of the number of variables in relation to the risk of relapse and OS. Multivariate Cox's regression analysis was used to determine factors independently associated with outcome. Both these methods of analysis (proportions and Kaplan-Meier) provide different information and have thus been presented. 23 All P-values quoted are two sided. Analyses were carried out using SAS statistical software, version 9.1 (SAS Institute Inc., Cary, NC, USA), and in-house programs.
Results
A total of 5637 children with ALL were enrolled in Medical Research Council clinical trials in childhood ALL over this 17-year period (1985-2001) . In all, 73 (1.3%) failed to achieve remission and were excluded from further analyses ( Table 1) . Of the 5564 evaluable patients, 1748 (31%) experienced relapse of whom 1168 (67%) were n-CNSr, 273 (16%) were c-CNSr and 307 (18%) were i-CNSr (Table 2) . A total of 93 (1.7%) children had CNS disease at original diagnosis, of whom 27 subsequently relapsed.
Change in incidence and pattern of central nervous system (CNS) relapses with protocols
During this period, both EFS and OS have improved with significant declines in both CNS and non-CNS relapses (Figures 1a-c and Table 2 ). Among those who relapsed in the CNS, the proportion with c-CNSr has fallen (P ¼ 0.0001) whereas the proportion of i-CNSr has remained relatively unchanged (P ¼ 0.8; Table 2 ).
Change in time to central nervous system (CNS) relapse with protocols
Along with the decrease in relapse rates, the duration of first complete remission before relapse has also changed ( Table 3) . As the lowest relapse rates were observed with ALL97/99, a comparison has been made between ALL97/99 and all previous trials. Among relapsing patients, although the proportion of very early relapses is similar for pre-ALL97/99 and ALL97/99, there has been a drop in the proportion of early relapses, and an increase in late relapses (Po0.0001). This change in the timing of relapse with trials is also observed in c-CNSr (P ¼ 0.01) and n-CNSr (P ¼ 0.0004), but not in i-CNSr (P ¼ 0.5). Table 4 shows the influence of risk factors on recurrence. Age, WBC count and NCI risk group were significant risk factors across all relapse categories. Unlike n-CNSr, gender was not a risk factor for CNS relapse. Immunophenotype influenced i-CNSr and n-CNSr but not c-CNSr. When analysed by trial, there were no differences in the effect of risk factors, with two exceptions (data not shown). First, the effect of gender on n-CNSr differed significantly by trial protocol (P(heterogeneity) ¼ 0.0001), with the greatest effect observed in the earlier trials. Second, although there was a suggestion that the Relapse, childhood acute lymphoblastic leukaemia S Krishnan et al Age at diagnosis (years) o2 (%) 163 (10) 157 (8) 76 (8) 63 (7) 2-9 (%)
Factors influencing risk of central nervous system (CNS) relapse
1212 (75) 1617 (77) 716 (72) 680 (72) X10 (%)
237 (15) 316 (15) 205 (20) 195 ( 342 (21) 462 (22) 227 (23) 221 (24) Immunophenotype Non T-cell (%) 1397 (86) 1730 (83) 863 (86) 831 (88) T-cell (%)
139 (9) 206 (10) 118 (12) 92 (10) Unknown (%)
76 (5) 154 (7) 16 (2) 15 (2) CNS disease at diagnosis 
Second malignant neoplasms (deaths) 30 (18) 16 (12) 33 or cytogenetics. In UKALLXI very high-risk patients were recommended transplant and hence received total body irradiation rather than XRT or HDM. In ALL97, very high-risk patients were treated on HR1.
Relapse, childhood acute lymphoblastic leukaemia S Krishnan et al effect of the T-cell immunophenotype on i-CNSr differed with trial (P(heterogeneity) ¼ 0.02), this was no longer observed when the less-than-robust data from UKALLX were excluded from the analyses (P ¼ 0.6).
We have sufficient data to analyse the pattern of relapses in the four main cytogenetic subtypes (Table 5 ). There was a significant decrease in relapse rates in ETV6-RUNX1 patients over successive protocols (Po0.0001). The change in pattern was similar to that observed for the whole group, that is, a proportionate decrease in c-CNSr but not in i-CNSr with time.
Patients with HH ALL also showed a significant decline in relapse rates (Po0.0001), primarily between UKALLXI and ALL97. Unlike in ETV6-RUNX1 patients, there was no apparent change in relapse pattern, with the proportion of i-CNSr and c-CNSr remaining essentially unchanged over the trials (Table 5) . Although numbers were small, there were also suggestions of a decrease in relapse rates over time in those with MLL (P(trend) ¼ 0.009) and t(9;22) (P(trend) ¼ 0.05) rearrangements. A decline in i-CNSr was observed in t(9;22) disease, with none observed in the later trials. However increasingly with trials, patients with adverse cytogenetic subtypes received an allograft in first complete remission and thus in ALL97 and ALL97/99, most patients with t(9;22) and MLL rearrangements would have been transplanted. 24 
Outcome after central nervous system (CNS) relapse
Similar to the Children's Oncology Group experience, 8 the overall outcome was significantly better in patients with i-CNSr (P ¼ 0.04; Supplementary Information). Supplementary Figures S1A-C show differences in OS after relapse in each relapse category by trial. There were excess relapses in UKALLXI (Table 2 ) but many patients were subsequently salvaged. Excluding UKALLXI, there is no significant difference in OS after relapse for UKALLX, ALL97 and ALL97/99. The 5-year OS after c-CNSr in UKALLX and ALL97/99 are comparable. Although OS after n-CNSr seemed to be better, and for i-CNSr worse in ALL97/99, these differences are not statistically significant when compared with UKALLX.
The prognostic significance of a number of variables in relation to outcome after relapse is shown in Table 6 . Univariate analyses showed that time to relapse, WBC count, adverse cytogenetics and NCI risk group were predictive of OS for all categories of relapse. As with n-CNSr, age and HH were predictive for OS in i-CNSr whereas immunophenotype and the ETV6-RUNX1 genotype significantly influenced OS after relapse in c-CNSr. Multivariate analysis, after exclusion of cytogenetic subtypes due to small numbers and missing data, confirmed the independent prognostic effect of time to relapse on OS after relapse in all three relapse categories. Additional factors independently and significantly associated with OS after relapse were WBC count (i-CNSr and n-CNSr) and the blast immunophenotype (c-CNSr and n-CNSr).
Besides time to relapse, multivariate analysis indicated that the trial period significantly influenced OS after relapse across all relapse categories. The choice of steroid in frontline therapy has been reported to influence outcome. 15 Overall, EFS was significantly higher with frontline dexamethasone treatment (Table 1) , although within trials, this effect was observed in ALL97 and not in ALL97/99. However, frontline steroid therapy had no significant influence on OS in relapsed patients who were randomized to receive either prednisolone 40 mg/m 2 (n ¼ 280) or dexamethasone 6.5 mg/m 2 (n ¼ 120) in frontline protocols (P ¼ 0.4). This was equally true for OS after relapse in each relapse category (P(heterogeneity) ¼ 0.2)) although the numbers in these subgroups were small.
Transplantation
The proportion of patients treated with an allogeneic stem cell transplant has decreased progressively with each trial (Po0.0001) as has the proportion of transplants carried out after relapse over time (P(trend) ¼ 0.0007; Supplementary Table  S1 ). There was no significant variation in the proportion of patients receiving a transplant after i-CNSr or n-CNSr over the study period. There was a decrease in stem cell transplant for those with c-CNSr (P ¼ 0.02), although the numbers are small for ALL97/99. In patients transplanted after CNS relapse (i-CNSr or c-CNSr), the 2-year OS, as defined from the date of transplant, was 46% (95% confidence interval 34-58%) in UKALLX, 64% (56-72%) in UKALLXI, 55% (40-70%) in ALL97 and 65% (40-90%) in ALL97/99. Comparison of outcome between patients treated with chemotherapy only and those treated with stem cell transplant has not been attempted due to the inherent bias in therapy selection.
Discussion
Our analyses confirm that the current UK therapy for ALL is effective in preventing extramedullary relapses in most children. This does not adequately explain why the decline in CNS relapses is observed predominantly in combined relapses or the proportionately little change in the pattern of i-CNSr with progressive trials.
Although UKALLXI investigated different CNS-directed therapies, the highest incidence of all relapses, and notably c-CNSr, were observed during this era. In UKALLX, all children Table 2 Number of relapses in each relapse category by trial Abbreviations: c-CNSr, combined central nervous system relapse; i-CNSr, isolated CNS relapse; n-CNSr, non-CNS relapse. Numbers in brackets represent the percentage of proportions (equivalent to competing risk cumulative incidence) within each relapse category for all patients (top) and for all relapses (bottom in italics). P-values are for heterogeneity between trials.
Relapse, childhood acute lymphoblastic leukaemia S Krishnan et al Figure 1 Kaplan-Meier analysis of cumulative incidence of site-specific relapse censored for death in remission or alternative site of relapse.
(a) Isolated central nervous system relapse (i-CNSr) (b) combined CNS relapse (c-CNSr) and (c) non-CNS relapse (n-CNSr). P-values are for heterogeneity between trials.
Relapse, childhood acute lymphoblastic leukaemia S Krishnan et al received cranial irradiation and an anthracycline during induction. 16 In ALL97/99, anthracyclines were only given to NCI high-risk patients or those with poor early response to therapy, 15, 20 and radiotherapy was reserved for those with CNS disease at diagnosis. Nevertheless, there is a significant decrease in relapse rates in all categories in ALL97/99. Thus, CNS recurrence can largely be prevented without the use of highdose methotrexate or cranial irradiation. The more frequent use of intrathecal methotrexate is contributory, but as this was introduced in UKALLXI, it is not the sole factor. In ALL97 and ALL97/99, steroid therapy was randomized between prednisolone and dexamethasone. The latter is thought to have better Table 3 Changing trends in time to relapse from first diagnosis in children treated in MRC ALL protocols Abbreviations: c-CNSr, combined central nervous system relapse; i-CNSr, isolated CNS relapse; MRC-ALL, Medical Research Council-acute lymphoblastic leukaemia; n-CNSr, non-CNS relapse. A comparison is made between ALL97/99 and all other trials. When compared with earlier trials, c-CNSr and n-CNSr occur later in ALL97/99. The proportion and timing of i-CNSr remains unchanged. Numbers in brackets are percentages of total relapses in each category. P-values for heterogeneity between trials correspond to comparison of pre-ALL97/99 trials with ALL97/99. Abbreviations: c-CNSr, combined central nervous system relapse; i-CNSr, isolated CNS relapse; NCI, National Cancer Institute; n-CNSr, non-CNS relapse; O/E, observed/expected ratio; WBC, white blood cell.
Relapse, childhood acute lymphoblastic leukaemia S Krishnan et al penetration into the CNS. Although significant improvements in EFS and in both CNS and non-CNS relapse rates were observed with dexamethasone, there was no difference in OS. 15 In addition, there was no significant heterogeneity of effect of the randomized steroid on outcome by trial. Thus, other chemotherapeutic changes in ALL97/99 are primarily responsible for the improvement in outcome between ALL97 and ALL97/99. In ALL97/99, UKALLX/ALL97 intensification phases were replaced with Berlin-Frankfurt-Mü nster-type consolidation blocks, therapy was risk stratified and intrathecal therapy was extended. The duration of therapy for boys was extended to 3 years, and hence from 1998 most boys received 3 instead of 2 years of therapy. The additional randomization of 6-mercaptopurine with 6-thioguanine found the latter to be not only protective against i-CNSr, but also hepatotoxic. 19 Although synergy with dexamethasone is a possibility, neither 6-thioguanine nor its active metabolites cross the blood brain barrier. 19 Thus, the evidence suggests that risk-stratified intensification of systemic therapy along with frequent intrathecal chemotherapy is the most successful approach for prevention of CNS relapse. A similar observation has been reported by Children's Oncology Group in the Children's Cancer Group-1961 study. Children receiving early post-induction intensification of therapy showed a significant decrease in n-CNSr and c-CNSr but not i-CNSr. 25 Thus, both intensification and more frequent intrathecal therapy seem to have a role in the decline in CNS relapses.
With multi-agent chemotherapy, it is difficult to identify the key responsible agent(s). The differential relapse trends in the cytogenetic subtypes offer room for speculation. In patients with ETV6-RUNX1, the incidence of relapses has progressively decreased with each successive protocol from UKALLXI onwards. Further decline in ETV6-RUNX1-associated relapses in ALL97/99 occurs primarily in the c-CNSr group. We have already commented on the fact that the improvement in outcome with ALL97/99 cannot be attributed to dexamethasone alone. ETV6-RUNX1 leukaemias are thought to benefit from intensive asparaginase therapy. 26, 27 UKALLXI and ALL97 used suboptimal doses of Erwinase. The improved outcome of ETV6-RUNX1 patients in ALL97/99 is probably related to the more effective use of Escherichia coli asparaginase (Elspar, Merck, Whitehouse Station, NJ, USA) in this trial. The additional intensification of asparaginase therapy in ALL2003 is expected to further reduce ETV6-RUNX1 relapses. In HH ALL, a predilection for extramedullary relapses in patients treated on contemporary chemotherapy regimens has been reported from a single centre. 28 Although relapses in HH patients halved in ALL97, ALL97/99 provided no apparent further benefit, and overall, the proportion of i-CNSr and c-CNSr has remained the same over trials. HH ALLs are more likely to be responsive to intensive methotrexate regimens. 28, 29 In UKALLXI, high-dose intravenous methotrexate was found to be protective against i-CNSr. 13 The relapse rate for HH is also lower in this protocol Abbreviations: c-CNSr, combined central nervous system relapse; HH, high hyperdiploidy; i-CNSr, isolated CNS relapse; MLL, mixed-lineage leukaemia; n-CNSr, non-CNS relapse. The rise in incidence of translocation-associated leukaemias in the later trials reflects the use of FISH screening. The proportion of children in each cytogenetic group does not differ by trial, with the exception of MLL rearrangements (infants included in UKALLX but not in UKALLXI). The numbers screened represent the number of patients in each trial with available cytogenetic data. Numbers in brackets represent percentages of total relapses in each group.
Relapse, childhood acute lymphoblastic leukaemia S Krishnan et al than that for ETV6-RUNX1. It is thus tempting to postulate that outcome in patients with HH may be further improved by the targeted reintroduction of high-dose intravenous methotrexate in future trials. Thus, there are still opportunities to biologically adapt current therapy to improve outcomes. Although the incidence of relapse has decreased with time, the outcomes after relapse have not improved. This suggests that by optimizing treatment, we are now preventing relapses in those who were earlier cured with salvage therapy. Given our incomplete understanding of why CNS relapses occur and the paucity of new agents, the best therapeutic strategy remains unclear. The results of transplantation in children with i-CNSr relapses have been variable. 7, 8, 11, [30] [31] [32] In retrospect, a number of children who were transplanted for disease recurrence in earlier trials would have been cured by current chemotherapy. The standard approach for those who are not transplanted is chemoradiotherapy. However, there is little consensus on the dose, type and timing of CNS irradiation. 2 Radiotherapy no longer has a role in preventing CNS relapses in frontline therapy.
Is it really of benefit as a therapeutic adjunct to systemic chemotherapy in relapsed disease? This is a difficult question to answer as the small numbers and heterogeneity of disease preclude a randomized approach to this problem. At the moment the most effective strategy remains prevention of disease recurrence. Our analyses suggest that both the biological heterogeneity of the disease and combined systemic and intrathecal chemotherapy influence the incidence and pattern of CNS relapse. Thus, further optimization with currently available agents is possible and may further decrease CNS recurrence.
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